Ensifentrine (Ohtuvayre), a novel medication for the treatment of chronic obstructive pulmonary disease (COPD) recently approved by the US Food and Drug Administration, has been shown to reduce COPD ...
A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...
In addition, symptoms and effective treatments can change quite a bit as the disease gets worse, so it’s good to stay vigilant and check in with your doctor on a regular basis. Wherever you are on ...
AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...
FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
While COPD (chronic obstructive pulmonary disease) symptoms may start out as mild to moderate — with episodes of difficulty breathing that come and go — over time, COPD tends to get worse, and many ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback